Avinger Successfully Completes VISION IDE Trial for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Avinger Successfully Completes VISION IDE Trial for Pantheris(TM)

REDWOOD CITY, Calif., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ: AVGR ) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced that its Pantheris™ system has achieved all safety and efficacy endpoints in six-month follow-up data for its VISION IDE clinical trial. VISION was designed to evaluate the safety and effectiveness of Pantheris to perform directional atherectomy while for the first time ever allowing physicians to use real-time intravascular imaging to aid in the removal of plaque from diseased lower extremity arteries.

VISION results from the 130 patients treated per protocol in the study were presented today at the Vascular Interventional Advances (VIVA) 2015 annual meeting by Arne Schwindt, M.D. of St. Franziskus Hospital in Muenster, Germany, one of the lead principal investigators.

Final VISION trial results demonstrated:

  • Primary efficacy endpoint of residual stenosis less than or equal to 50% following Pantheris treatment was achieved in 96.3% (158/164) of lesions, significantly outperforming the pre-defined study goal of 87%;
  • Target lesion revascularization (TLR) rate of 8.0% and overall major adverse event (MAE) rate of 17.6% through six-month follow-up, measuring below the pre-defined study limit for MAEs of 43.2%;
  • Zero clinically significant dissections, perforations, or late aneurysms related to Pantheris;
  • Statistically significant improvement across all patients in both blood flow measurement (Ankle Brachial Index) and symptom-based outcomes (Rutherford Classification);
  • Stent placement in only 4% of lesions following treatment with Pantheris;
  • Six-month TLR of 6.5% in chronic total occlusion (CTO) subgroup (n=31) with only one instance of adjunctive stent placement; and
  • Only 1% adventitia in tissue removed, on average, across all lesions treated.

Commenting on the results of the VISION trial, Dr. Schwindt said, "The positive final data supports the interim results achieved in the first 93 patients, and further highlights the benefit Pantheris offers in treating patients with PAD. Patients experienced no dissections, no perforations, and no late aneurysms related to Pantheris treatment. Moreover, histology confirms the precision of Optical Coherence Tomography (OCT) guidance to aid in the removal of plaque from diseased lower extremity arteries."

The average percent area of adventitia, an indicator of arterial wall disruption, in the atherectomy tissue samples collected was just 1.0% across all lesions treated and analyzed for histology. This histologic analysis highlights the tremendous precision that real-time OCT guidance enables during directional atherectomy, and confirms that real-time imaging provides the feedback necessary for physicians to treat PAD without damaging normal arterial structures such as adventitia.

"Through all aspects of the VISION trial, starting with design, then enrollment, then execution and follow-up, I personally could not have predicted a better outcome. For sure, the results reflect what happens when truly unique devices are investigated by serious investigators working in a collaborative effort with the FDA," said John B. Simpson, Ph.D., M.D., Founder and Executive Chairman of Avinger. "Never before have I been involved in a trial with such consistently positive outcomes. I am confident that we have opened the door on the development of technology that will significantly improve the treatment of peripheral arterial disease."

On October 14, 2015, Avinger received FDA clearance of Pantheris based on an interim analysis of 93 patients. The final data analysis of all patients treated per protocol (n=130) has been filed with the FDA to supplement the 510(k) clearance.

About VISION

VISION is a non-randomized, prospective, global, single-arm clinical trial that is evaluating the safety and effectiveness of the Pantheris TM system to perform directional atherectomy while using intravascular imaging to aid in the removal of plaque from diseased lower extremity arteries. The study enrolled 134 patients and includes follow-up data collection review by independent third parties at thirty days and six months.

About Pantheris™

Pantheris is the first-ever image-guided atherectomy device using real-time intravascular visualization technology. Pantheris is the subject of the VISION IDE trial, a ground-breaking study designed to evaluate its safety and efficacy for directional atherectomy in the peripheral arteries, while allowing physicians to use high resolution Optical Coherence Tomography (OCT) intravascular imaging to aid in the removal of plaque from diseased lower extremity arteries. 

About Avinger, Inc.

Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral arterial disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The Company's mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger's current lumivascular products include the Lightbox™ imaging console, the Ocelot™ family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris™, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit the Company's website at www.avinger.com .

"Avinger ," " Pantheris " and the Avinger logo are registered trademarks of Avinger, Inc.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the clinical benefits of Pantheris and adoption of Pantheris for treatment of PAD. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include our dependency on a limited number of products; ability to demonstrate the benefits of our lumivascular platform; the resource requirements related to Pantheris; the outcome of clinical trial results including our VISION Trial; potential exposure to third-party product liability and intellectual property litigation; lack of long-term data demonstrating the safety and efficacy of our lumivascular platform products; reliance on third-party vendors; dependency on physician adoption; reliance on key personnel; and requirements to obtain regulatory approval to commercialize our products; as well as the other risks described in the section entitled "Risk Factors" in our Form 10-Q filing made with the Securities and Exchange Commission on August 12, 2015. These forward-looking statements speak only as of the date hereof. Avinger disclaims any obligation to update these forward-looking statements.

Media Contact: Bart Beasley VP of Marketing, Avinger Phone: +1 650 241 7900 Email: Investor Contact: Leigh Salvo Westwicke Partners Phone: +1 415 513 1281 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 0

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 51

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 493

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 326

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 349

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 11

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 187

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 483

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 197

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading

Top 5 Most Recently Viewed Articles

Integer Holdings Opens Conversion on 2.125% Senior Notes

Updated Category News Views 151

Integer Holdings Announces Conversion of Senior Notes Integer Holdings Corporation (NYSE: ITGR) has recently made headlines with the announcement that its 2.125% Convertible Senior Notes, due in 2028, are now eligible for conversion. This pivotal move allows holders to convert their notes into either cash, common stock, or a combination of both. The option to convert is...

Continue Reading
Investors Urged to Consider Class Action Against Micron Technology

Updated Category News Views 119

Class Action Lawsuit Against Micron Technology, Inc. Levi & Korsinsky, LLP has alerted investors in Micron Technology, Inc. (NASDAQ: MU) regarding an ongoing class action securities lawsuit. This legal action aims to represent those investors who may have incurred financial losses during a specified period. Investors are encouraged to stay informed regarding this...

Continue Reading
Expansion Grant from Bradford White Boosts ECA Internship Program

Updated Category News Views 88

Bradford White Fuels Growth in ECA Internship Program Bradford White Corporation, known for its innovative water heating solutions, has committed $50,000 towards expanding the Energy Coordinating Agency's (ECA) internship program focused on heat pump technology. This initiative aims to enhance training opportunities for the next generation of plumbing and HVAC...

Continue Reading
Industrial Automation Market Set for Significant Growth Ahead

Updated Category News Views 199

Transformations in the Industrial Automation Market Landscape The industrial automation sector is undergoing a major shift as manufacturers worldwide increasingly adopt Industry 4.0 technologies and artificial intelligence. This evolution is spurred by pressing challenges including labor shortages and the need for enhanced operational efficiency. The market is projected...

Continue Reading
Exploring Competitive Landscape of Amazon.com in Retail Sector

Updated Category News Views 159

Understanding Amazon.com's Competitive Position In today's dynamic business world, understanding how companies perform against their competitors is essential. This article delves into a detailed examination of Amazon.com (NASDAQ: AMZN) and compares it with key rivals in the broadline retail sector. By exploring crucial financial data, market strategies, and growth...

Continue Reading